NL1032132A1 - Nieuwe MAdCAM-antilichamen. - Google Patents
Nieuwe MAdCAM-antilichamen.Info
- Publication number
- NL1032132A1 NL1032132A1 NL1032132A NL1032132A NL1032132A1 NL 1032132 A1 NL1032132 A1 NL 1032132A1 NL 1032132 A NL1032132 A NL 1032132A NL 1032132 A NL1032132 A NL 1032132A NL 1032132 A1 NL1032132 A1 NL 1032132A1
- Authority
- NL
- Netherlands
- Prior art keywords
- new
- madcam antibodies
- madcam
- antibodies
- new madcam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69745305P | 2005-07-08 | 2005-07-08 | |
US69745305 | 2005-07-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
NL1032132A1 true NL1032132A1 (nl) | 2007-01-09 |
NL1032132C2 NL1032132C2 (nl) | 2007-10-09 |
Family
ID=37637550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1032132A NL1032132C2 (nl) | 2005-07-08 | 2006-07-07 | Nieuwe MAdCAM-antilichamen. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20070009536A1 (nl) |
EP (1) | EP1904531B1 (nl) |
JP (1) | JP2009500390A (nl) |
AR (1) | AR054539A1 (nl) |
AT (1) | ATE483732T1 (nl) |
CA (1) | CA2614314A1 (nl) |
DE (1) | DE602006017373D1 (nl) |
DO (1) | DOP2006000162A (nl) |
ES (1) | ES2351057T3 (nl) |
GT (1) | GT200600297A (nl) |
NL (1) | NL1032132C2 (nl) |
PE (1) | PE20070374A1 (nl) |
TW (1) | TW200740844A (nl) |
UY (1) | UY29653A1 (nl) |
WO (1) | WO2007007173A2 (nl) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
ES2362667T3 (es) * | 2004-01-09 | 2011-07-11 | Pfizer Inc. | ANTICUERPOS FRENTE A MAdCAM. |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2007007162A1 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
WO2013126595A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye And Ear Infirmary | Methods for treating corneal and conjunctival inflammation and inflammatory disorders |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
DK2900265T3 (en) | 2012-09-27 | 2018-08-20 | Biocare Medical Llc | Anti-Uroplakin II Antibodies, Systems and Methods |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
WO2014134587A1 (en) | 2013-02-28 | 2014-09-04 | Biocare Medical, Llc | Anti-p40 antibodies systems and methods |
DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CA2916283A1 (en) | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗muc1* 抗体 |
WO2017106326A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
EP3652211A1 (en) | 2017-07-14 | 2020-05-20 | Pfizer Inc. | Antibodies to madcam |
TW202110885A (zh) * | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040010810A1 (en) * | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
WO1996024673A1 (en) * | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
CA2290485C (en) * | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
EP1078006B1 (en) * | 1998-05-13 | 2009-03-04 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
ES2278463T3 (es) * | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
ES2362667T3 (es) * | 2004-01-09 | 2011-07-11 | Pfizer Inc. | ANTICUERPOS FRENTE A MAdCAM. |
-
2006
- 2006-07-05 PE PE2006000803A patent/PE20070374A1/es not_active Application Discontinuation
- 2006-07-05 CA CA002614314A patent/CA2614314A1/en not_active Abandoned
- 2006-07-05 ES ES06795104T patent/ES2351057T3/es active Active
- 2006-07-05 JP JP2008520019A patent/JP2009500390A/ja active Pending
- 2006-07-05 AT AT06795104T patent/ATE483732T1/de not_active IP Right Cessation
- 2006-07-05 EP EP06795104A patent/EP1904531B1/en not_active Not-in-force
- 2006-07-05 DE DE602006017373T patent/DE602006017373D1/de active Active
- 2006-07-05 WO PCT/IB2006/001923 patent/WO2007007173A2/en not_active Application Discontinuation
- 2006-07-06 AR ARP060102918A patent/AR054539A1/es unknown
- 2006-07-06 UY UY29653A patent/UY29653A1/es not_active Application Discontinuation
- 2006-07-06 DO DO2006000162A patent/DOP2006000162A/es unknown
- 2006-07-06 GT GT200600297A patent/GT200600297A/es unknown
- 2006-07-07 TW TW095124814A patent/TW200740844A/zh unknown
- 2006-07-07 NL NL1032132A patent/NL1032132C2/nl not_active IP Right Cessation
- 2006-07-10 US US11/484,456 patent/US20070009536A1/en not_active Abandoned
-
2009
- 2009-04-23 US US12/429,154 patent/US7935794B2/en not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,532 patent/US20110165167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE602006017373D1 (de) | 2010-11-18 |
GT200600297A (es) | 2007-02-14 |
NL1032132C2 (nl) | 2007-10-09 |
UY29653A1 (es) | 2007-02-28 |
WO2007007173A3 (en) | 2007-05-10 |
US20110165167A1 (en) | 2011-07-07 |
JP2009500390A (ja) | 2009-01-08 |
ATE483732T1 (de) | 2010-10-15 |
PE20070374A1 (es) | 2007-05-12 |
US20070009536A1 (en) | 2007-01-11 |
EP1904531A2 (en) | 2008-04-02 |
TW200740844A (en) | 2007-11-01 |
ES2351057T3 (es) | 2011-01-31 |
WO2007007173A2 (en) | 2007-01-18 |
EP1904531B1 (en) | 2010-10-06 |
AR054539A1 (es) | 2007-06-27 |
CA2614314A1 (en) | 2007-01-18 |
DOP2006000162A (es) | 2007-01-31 |
US7935794B2 (en) | 2011-05-03 |
US20090214558A1 (en) | 2009-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL1032132A1 (nl) | Nieuwe MAdCAM-antilichamen. | |
NL1027975A1 (nl) | Antilichamen tegen MAdCAM. | |
NL300935I2 (nl) | guselkumab. | |
LTC1963368I2 (lt) | Anti-il-17 antikūnai | |
NL1028927A1 (nl) | Nieuwe verbindingen. | |
NO20076607L (no) | TWEAK - bindende antistoff | |
DK3332808T3 (da) | Humaniserede L243-antistoffer | |
DK1964852T3 (da) | Anti-ilt7-antistof | |
NO20071430L (no) | Anti-OX4OL antistoffer | |
DK2251351T4 (da) | Sclerostinepitoper | |
SG10201404801YA (en) | Monoclonal antibody | |
NO20051199L (no) | Rorhandteringsutstyr. | |
NO20053136D0 (no) | Drikk. | |
GB0517487D0 (en) | Antibodies | |
NO20053362L (no) | Syklofuge. | |
BRPI0509495A2 (pt) | anticorpo humanizado | |
DE602006009608D1 (de) | Synchronisierungseinrichtung | |
DE502006001058D1 (de) | Synchronisiereinrichtung | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
DE602005017083D1 (de) | Getränkefass | |
GB0505489D0 (en) | Antibodies | |
BRPI0718609A2 (pt) | Anticorpos modificadores de doença cancerosa. | |
GB0512278D0 (en) | Antibodies | |
GB0505054D0 (en) | Antibodies | |
NL1030485A1 (nl) | Nieuwe verbindingen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AD1A | A request for search or an international type search has been filed | ||
RD2N | Patents in respect of which a decision has been taken or a report has been made (novelty report) |
Effective date: 20070607 |
|
PD2B | A search report has been drawn up | ||
VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20100201 |